A great place to work, according to Science

AbbottAbbott is among the best science-based companies to work for in the world. For the 13th consecutive year, the journal Science recognized Abbott on its Top Employers list, evaluated on 23 characteristics including financial strength, easy adaptation to change and a having a research-driven environment.

"Abbott is unique in that we've been adding to our reservoir of scientific knowledge for 128 years," said John Frels, Ph.D., chair of Abbott's Scientific Governing Board, which oversees the company's senior scientific career track. "We strive to bring in the best and brightest scientists and engineers to work on some of the biggest problems in healthcare today. This helps us to create new, breakthrough innovations that change people's lives."

The clarity of Abbott's mission to help people live better, fuller lives through the power of health creates an environment that fosters growth and development as a scientist, Frels said - and ultimately leads to our next great innovations.

"We place great importance on the patient - the person that our products are ultimately designed to help." Frels said. "And that appeals to the hearts and the minds of our scientists - they know that what they're doing is making a difference in people's lives."

Scientists at Abbott are given opportunities to advance science, technology, medicine and nutrition to help people live fuller and more complete lives. The company recognizes this commitment through a number of internal recognition efforts, including chairman's awards, president's awards, and patent and inventor awards. The company honors its most distinguished scientists and engineers with induction into the prestigious Volwiler Society, named for the late Ernest H. Volwiler, Ph.D., an internationally recognized scientist and former Abbott president and chairman of the board.

In addition to being honored for workplace leadership by Science, FORTUNE magazine has named Abbott as one of "America's Most Admired Companies" every year since the list's inception in 1983. Working Mother and DiversityInc magazines have also ranked Abbott as a top employer, and the National Association for Female Executives again named Abbott among the Top 50 Companies for Executive Women in 2016.

About the 2016 Science Survey
Nearly 6,000 scientists from around the world (56 percent North America; 28 percent Europe; and 12 percent Asia/Pacific Rim) voted on the companies they considered the best, average and worst employers. Here's a complete list of the rankings, which are also available in the Oct. 28, 2016, print edition of Science.

About Abbott
At Abbott, we're committed to helping you live your best possible life through the power of health. For more than 125 years, we've brought new products and technologies to the world - in nutrition, diagnostics, medical devices and branded generic pharmaceuticals - that create more possibilities for more people at all stages of life.

Today, 74,000 of us are working to help people live not just longer, but better, in the more than 150 countries we serve.

Most Popular Now

Sanofi builds focus on rare blood disorders and ca…

Some of the most serious unmet patient needs today are in the field of hematology. Rare blood disorders and blood-related cancers continue to be a major focus of research...

Novartis rises to second place in 2018 Access to M…

Novartis ranked second in the 2018 Access to Medicine Index (ATMi), up from 3rd place in 2016, in recognition of its long-standing efforts to improve worldwide access to ...

FDA approves first treatment for Lambert-Eaton mya…

The U.S. Food and Drug Administration today approved Firdapse (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. LEMS is a r...

Pfizer reaches a global agreement with AbbVie

Pfizer Inc. (NYSE:PFE) has signed licensing agreements with AbbVie, resolving all global intellectual property matters for Pfizer's proposed adalimumab biosimilar. Under ...

FDA grants breakthrough device designation to arti…

Bayer announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation to the Artificial Intelligence Software for Chronic Thrombo...

FDA approves new treatment for patients with acute…

The U.S. Food and Drug Administration today approved Daurismo (glasdegib) tablets to be used in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for t...

U.S. FDA approves Larotrectinib, the first TRK inh…

The U.S. Food and Drug Administration (FDA) has approved larotrectinib, the first oral TRK inhibitor, under the brand name Vitrakvi®. The approval is for the treatment of...

GSK reaches agreement to acquire TESARO, an oncolo…

GlaxoSmithKline plc (LSE/NYSE: GSK) and TESARO Inc (NASDAQ: TSRO) announced that the Companies have entered into a definitive agreement pursuant to which GSK will acquire...

Merck and Pfizer provide update on avelumab in pla…

Merck and Pfizer Inc. (NYSE: PFE) today announced that the Phase III JAVELIN Ovarian 200 trial evaluating avelumab* alone or in combination with pegylated liposomal doxor...

Bristol-Myers Squibb awards "Golden Tickets…

Bristol-Myers Squibb Company (NYSE: BMY) and LabCentral, an innovative, shared laboratory space designed as a launchpad for life-sciences and biotech startups, today anno...

Alcon to highlight its vision, strategy and benefi…

Alcon, the eye care division of Novartis, will today hold its first Capital Markets Day for investors and analysts in relation to the previously-announced intention of No...

New study reveals probiotics do not help children …

Probiotics are a multibillion-dollar industry with marketing claims of being an effective treatment for a multitude of ailments, including diarrhea. However, findings fro...